Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1973 1
1978 1
1979 1
1982 1
1983 1
1985 1
1989 3
1999 3
2000 2
2001 3
2002 1
2003 2
2004 4
2005 3
2006 11
2007 12
2008 6
2009 10
2010 19
2011 24
2012 15
2013 15
2014 39
2015 61
2016 56
2017 44
2018 62
2019 73
2020 60
2021 63
2022 46
2023 50
2024 36
2025 43
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

678 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in pati …
BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative b …
Mitochondria--a bullseye in cancer therapy.
Gogvadze V, Zhivotovsky B. Gogvadze V, et al. Mitochondrion. 2014 Nov;19 Pt A:1-2. doi: 10.1016/j.mito.2014.10.002. Epub 2014 Oct 12. Mitochondrion. 2014. PMID: 25315654 No abstract available.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Pratz KW, et al. J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15. J Clin Oncol. 2022. PMID: 34910556 Free PMC article. Clinical Trial.
Goodbye Hartmann trial: a prospective, international, multicenter, observational study on the current use of a surgical procedure developed a century ago.
Perrone G, Giuffrida M, Abu-Zidan F, Kruger VF, Livrini M, Petracca GL, Rossi G, Tarasconi A, Tian BWCA, Bonati E, Mentz R, Mazzini FN, Campana JP, Gasser E, Kafka-Ritsch R, Felsenreich DM, Dawoud C, Riss S, Gomes CA, Gomes FC, Gonzaga RAT, Canton CAB, Pereira BM, Fraga GP, Zem LG, Cordeiro-Fonseca V, de Mesquita Tauil R, Atanasov B, Belev N, Kovachev N, Meléndez LJJ, Dimova A, Dimov S, Zelić Z, Augustin G, Bogdanić B, Morić T, Chouillard E, Bajul M, De Simone B, Panis Y, Esposito F, Notarnicola M, Lauka L, Fabbri A, Hentati H, Fnaiech I, Aurélien V, Bougard M, Roulet M, Demetrashvili Z, Pipia I, Merabishvili G, Bouliaris K, Koukoulis G, Doudakmanis C, Xenaki S, Chrysos E, Kokkinakis S, Vassiliu P, Michalopoulos N, Margaris I, Kechagias A, Avgerinos K, Katunin J, Lostoridis E, Nagorni EA, Pujante A, Mulita F, Maroulis I, Vailas M, Marinis A, Siannis I, Bourbouteli E, Manatakis DK, Tasis N, Acheimastos V, Maria S, Stylianos K, Kuzeridis H, Korkolis D, Fradelos E, Kavalieratos G, Petropoulou T, Polydorou A, Papacostantinou I, Triantafyllou T, Kimpizi D, Theodorou D, Toutouzas K, Chamzin A, Frountzas M, Schizas D, Karavokyros I, Syllaios A, Charalabopoulos A, Boura M, Baili E, Ioanni… See abstract for full author list ➔ Perrone G, et al. World J Emerg Surg. 2024 Apr 16;19(1):14. doi: 10.1186/s13017-024-00543-w. World J Emerg Surg. 2024. PMID: 38627831 Free PMC article.
Targeting the Redox Landscape in Cancer Therapy.
Narayanan D, Ma S, Özcelik D. Narayanan D, et al. Cancers (Basel). 2020 Jun 27;12(7):1706. doi: 10.3390/cancers12071706. Cancers (Basel). 2020. PMID: 32605023 Free PMC article. Review.
Mutations in the redox landscape can induce carcinogenesis, whereas increased ROS production can perpetuate cancer development. Moreover, cancer cells can increase production of antioxidants, leading to resistance against chemo- or radiotherapy. Research has been de …
Mutations in the redox landscape can induce carcinogenesis, whereas increased ROS production can perpetuate cancer development. Moreo …
Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD(7) in cancer.
Larasati Y, Boudou C, Koval A, Katanaev VL. Larasati Y, et al. Drug Discov Today. 2022 Mar;27(3):777-792. doi: 10.1016/j.drudis.2021.12.008. Epub 2021 Dec 13. Drug Discov Today. 2022. PMID: 34915171 Free article. Review.
Hence, the targeting of pathway component(s) that are essential for cancer but dispensable for normal physiology is key to the development of a safe Wnt signaling inhibitor. Frizzled(7) (FZD(7)) is a Wnt pathway receptor that is redundant in healthy tissues but crucial in …
Hence, the targeting of pathway component(s) that are essential for cancer but dispensable for normal physiology is key to the develo …
Mitophagy: Link to cancer development and therapy.
Kulikov AV, Luchkina EA, Gogvadze V, Zhivotovsky B. Kulikov AV, et al. Biochem Biophys Res Commun. 2017 Jan 15;482(3):432-439. doi: 10.1016/j.bbrc.2016.10.088. Epub 2017 Feb 3. Biochem Biophys Res Commun. 2017. PMID: 28212727 Review.
Thus, the analysis of crosstalk among the processes of mitophagy, cell death and tumorigenesis is important for the identification of targets responsible for the stimulation of cell death and selective elimination of cancer cells. In the present review, we analyze the mech …
Thus, the analysis of crosstalk among the processes of mitophagy, cell death and tumorigenesis is important for the identification of target …
Mitochondria as targets for cancer chemotherapy.
Gogvadze V, Orrenius S, Zhivotovsky B. Gogvadze V, et al. Semin Cancer Biol. 2009 Feb;19(1):57-66. doi: 10.1016/j.semcancer.2008.11.007. Epub 2008 Dec 3. Semin Cancer Biol. 2009. PMID: 19101636 Review.
Heterogeneity of tumors dictates an individual approach to anticancer treatment. Despite their variability, almost all cancer cells demonstrate enhanced uptake and utilization of glucose, a phenomenon known as the Warburg effect, whereas mitochondrial activity in tumor cel …
Heterogeneity of tumors dictates an individual approach to anticancer treatment. Despite their variability, almost all cancer cells d …
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?
Wagner SC, Ichim TE, Ma H, Szymanski J, Perez JA, Lopez J, Bogin V, Patel AN, Marincola FM, Kesari S. Wagner SC, et al. J Transl Med. 2015 Oct 29;13:340. doi: 10.1186/s12967-015-0688-5. J Transl Med. 2015. PMID: 26510973 Free PMC article. Review.
Vaccination with angiogenic antigens to generate cellular and/or humoral immunity against the tumor endothelium has proven to be a promising strategy for inhibiting or normalizing tumor angiogenesis and reducing cancer growth. Here we review tumor endothelium vaccines deve …
Vaccination with angiogenic antigens to generate cellular and/or humoral immunity against the tumor endothelium has proven to be a promising …
678 results